title: Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Cortese
authors.forename: Ashok L
authors.initials: AL
authors.lastname: Gowda
authors.forename: Anil
authors.initials: A
authors.lastname: Wali
authors.forename: James F
authors.initials: JF
authors.lastname: Eliason
authors.forename: Harvey I
authors.initials: HI
authors.lastname: Pass
authors.forename: Richard B
authors.initials: RB
authors.lastname: Everson
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics*; D000970:Antineoplastic Agents / Q000494:pharmacology; D004252:DNA Mutational Analysis; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000235:genetics* / Q000502:physiology; D000077156:Gefitinib; D005820:Genetic Testing; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics*; D008654:Mesothelioma / Q000188:drug therapy* / Q000235:genetics*; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D011799:Quinazolines / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib